Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company developing and commercializing inhaled therapies for cardiopulmonary disease — pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its PRINT particle-engineering technology underpins YUTREPIA, an inhaled treprostinil dry powder, and it is developing L606 (liposomal treprostinil inhalation suspension) with Pharmosa Biopharm.
- Website: https://www.liquidia.com/
- Backed by: canaan-partners
Liquidia publishes no public API, developer portal, SDK, or machine-readable interface as of 2026-07-19. The only machine-readable surfaces are the investor-relations RSS feeds (news releases, events, SEC filings). This repo is catalogued for network identity, corporate transparency, and domain-security coverage.
apis.yml— APIs.json 0.20 profilellms/liquidia-llms.txt— generated llms.txtsecurity/liquidia-domain-security.yml— probed TLS/DNS posturewell-known/liquidia-well-known.yml—/.well-known/inventory (verified absence)